

Attorney Docket No.: RTS-0235
Inventors: Bennett and Watt
Serial No.: 09/843,377
Filing Date: April 26, 2001
Page 2

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of the Claims:

Claim 1 (currently amended): A compound 8 to 50 nucleobases in length targeted to ~~a region encompassing a 5'-untranslated region, nucleobases 741 through 760, nucleobases 769 through 805, nucleobases 818 through 837, nucleobases 845 through 936, nucleobases 955 through 974, nucleobases 1000 through 1092, nucleobases 1144 through 1163, nucleobases 1180 through 1220, nucleobases 1233 through 1285, nucleobases 1291 through 1389, nucleobases 1399 through 1445, nucleobases 1496 through 1533, nucleobases 1540 through 1559, nucleobases 1575~~ 1000 through 1620 ~~1092 of a coding region, a stop codon region, or a 3'~~ untranslated region of a nucleic acid molecule encoding human Interferon gamma receptor 2 (SEQ ID NO: 3), wherein said compound is an antisense oligonucleotide which comprises at least one modified internucleoside linkage and wherein said compound specifically hybridizes with ~~one~~ of said regions and inhibits the expression of human Interferon gamma receptor 2.

Attorney Docket No.: RTS-0235
Inventors: Bennett and Watt
Serial No.: 09/843,377
Filing Date: April 26, 2001
Page 3

Claims 2-4 (canceled).

Claim 5 (currently amended): The compound of ~~claim-4~~
claim 1 wherein the modified internucleoside linkage is a
phosphorothioate linkage.

Claim 6 (currently amended): The compound of ~~claim-2~~
claim 1 wherein the antisense oligonucleotide comprises at least
one modified sugar moiety.

Claim 7 (original): The compound of claim 6 wherein the
modified sugar moiety is a 2'- α -methoxyethyl sugar moiety.

Claim 8 (currently amended): The compound of ~~claim-2~~
claim 1 wherein the antisense oligonucleotide comprises at least
one modified nucleobase.

Claim 9 (original): The compound of claim 8 wherein the
modified nucleobase is a 5-methylcytosine.

Claim 10 (currently amended): The compound of ~~claim-2~~
claim 1 wherein the antisense oligonucleotide is a chimeric
oligonucleotide.

Claim 11 (canceled).

Claim 12 (original): A composition comprising the compound
of claim 1 and a pharmaceutically acceptable carrier or diluent.

Attorney Docket No.: RTS-0235
Inventors: Bennett and Watt
Serial No.: 09/843,377
Filing Date: April 26, 2001
Page 4

Claim 13 (original): The composition of claim 12 further comprising a colloidal dispersion system.

Claims 14-20 (canceled).